MA35458B1 - Variants du facteur de croissance des fibroblastes 21 - Google Patents

Variants du facteur de croissance des fibroblastes 21

Info

Publication number
MA35458B1
MA35458B1 MA36861A MA36861A MA35458B1 MA 35458 B1 MA35458 B1 MA 35458B1 MA 36861 A MA36861 A MA 36861A MA 36861 A MA36861 A MA 36861A MA 35458 B1 MA35458 B1 MA 35458B1
Authority
MA
Morocco
Prior art keywords
variants
growth factor
fibroblast growth
fgf21
dyslipidemia
Prior art date
Application number
MA36861A
Other languages
English (en)
Inventor
Craig Duane Dickinson
David Albert Driver
Ryan James Darling
Malgorzata Donata Gonciarz
Radmila Micanovic
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46964112&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA35458(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA35458B1 publication Critical patent/MA35458B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des variants pharmacologiquement puissants et/ou stables du facteur de croissance 21 du fibroblaste humain (fgf21), des compositions pharmaceutiques comprenant des variants fgf21, ainsi que des procédés de traitement du diabète de type 2, l'obésité, la dyslipidémie, ou le syndrome métabolique, ou toute combinaison de ceux-ci, utilisant de tels variants.
MA36861A 2011-10-04 2014-03-27 Variants du facteur de croissance des fibroblastes 21 MA35458B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161542906P 2011-10-04 2011-10-04
PCT/US2012/057053 WO2013052311A1 (fr) 2011-10-04 2012-09-25 Variants du facteur de croissance 21 du fibroblaste

Publications (1)

Publication Number Publication Date
MA35458B1 true MA35458B1 (fr) 2014-09-01

Family

ID=46964112

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36861A MA35458B1 (fr) 2011-10-04 2014-03-27 Variants du facteur de croissance des fibroblastes 21

Country Status (28)

Country Link
US (2) US8541369B2 (fr)
EP (1) EP2763689B1 (fr)
JP (1) JP6060167B2 (fr)
KR (1) KR20140059271A (fr)
CN (1) CN103906530B (fr)
AP (1) AP2014007532A0 (fr)
AR (1) AR087973A1 (fr)
AU (1) AU2012318956A1 (fr)
BR (1) BR112014007532A2 (fr)
CA (1) CA2843520A1 (fr)
CL (1) CL2014000801A1 (fr)
CO (1) CO6910165A2 (fr)
CR (1) CR20140142A (fr)
DO (1) DOP2014000050A (fr)
EA (1) EA201490521A1 (fr)
EC (1) ECSP14013285A (fr)
ES (1) ES2548214T3 (fr)
IL (1) IL230754A0 (fr)
IN (1) IN2014CN00782A (fr)
MA (1) MA35458B1 (fr)
MX (1) MX2014004159A (fr)
PE (1) PE20142044A1 (fr)
PH (1) PH12014500740A1 (fr)
SG (1) SG11201401792UA (fr)
TN (1) TN2014000096A1 (fr)
TW (1) TWI461435B (fr)
WO (1) WO2013052311A1 (fr)
ZA (1) ZA201400882B (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2682147C (fr) 2007-03-30 2017-08-08 Ambrx, Inc. Polypeptides fgf-21 modifies, et leurs utilisations
US8951966B2 (en) 2011-07-01 2015-02-10 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides, and uses and methods thereof for treatment of metabolic disorders and diseases
JP2015522539A (ja) * 2012-05-15 2015-08-06 イーライ リリー アンド カンパニー 線維芽細胞増殖因子２１タンパク質の治療目的の使用
AU2013274639A1 (en) 2012-06-11 2014-11-06 Eli Lilly And Company Fibroblast growth factor 21 variants
TWI513705B (zh) * 2012-06-11 2015-12-21 Lilly Co Eli 纖維母細胞生長因子２１蛋白質
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
EP3798228A1 (fr) 2012-11-28 2021-03-31 NGM Biopharmaceuticals, Inc. Compositions et procédés pour le traitement de troubles métaboliques et de maladies
MX383664B (es) 2012-12-27 2025-03-14 Ngm Biopharmaceuticals Inc Uso de un péptido para modular la homeostasis de los ácidos biliares o tratamiento de una enfermedad relacionada con los ácidos biliares.
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
NZ718962A (en) 2013-10-28 2019-12-20 Ngm Biopharmaceuticals Inc Cancer models and associated methods
RS60593B1 (sr) 2014-01-24 2020-08-31 Ngm Biopharmaceuticals Inc Antitela koja vezuju domen 2 beta-kloto i postupci za njihovu upotrebu
WO2015138278A1 (fr) * 2014-03-11 2015-09-17 Novartis Ag Méthodes de traitement de troubles métaboliques associés à des lipodystrophies et à des défauts dans la production ou la signalisation de l'insuline
US10398758B2 (en) 2014-05-28 2019-09-03 Ngm Biopharmaceuticals, Inc. Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
EP3155005A4 (fr) 2014-06-16 2018-07-11 NGM Biopharmaceuticals, Inc. Procédés et utilisations pour la modulation de l'homéostasie de l'acide biliaire et le traitement de troubles et maladies de l'acide biliaire
SG11201702757YA (en) 2014-10-23 2017-05-30 Ngm Biopharmaceuticals Inc Pharmaceutical compositions comprising peptide variants and methods of use thereof
MX2017004947A (es) 2014-10-24 2017-06-29 Bristol Myers Squibb Co Polipeptidos del factor de crecimiento de fibroblastos 2 (fgf-21) modificados y usos de los mismos.
US10434144B2 (en) 2014-11-07 2019-10-08 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
US10800843B2 (en) 2015-07-29 2020-10-13 Ngm Biopharmaceuticals, Inc. Beta klotho-binding proteins
JP6728352B2 (ja) 2015-11-09 2020-07-22 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド 胆汁酸に関係した障害の治療方法
TW201731867A (zh) 2015-12-02 2017-09-16 賽諾菲公司 Ｆｇｆ２１變異體
WO2017220706A1 (fr) * 2016-06-22 2017-12-28 Novo Nordisk A/S Compositions pharmaceutiques de dérivés de fgf21 et leurs utilisations
US11370841B2 (en) 2016-08-26 2022-06-28 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors
CN106220724B (zh) * 2016-09-13 2019-10-11 河南师范大学 人成纤维细胞生长因子21重组蛋白及其制备方法和应用
CN106432509B (zh) * 2016-09-13 2019-05-21 河南师范大学 一种治疗代谢疾病的重组人成纤维细胞生长因子21融合蛋白及其制备方法和应用
CN106397607A (zh) * 2016-09-13 2017-02-15 河南师范大学 重组人成纤维细胞生长因子21融合蛋白及其在制备治疗代谢疾病药物中的应用
WO2018166461A1 (fr) 2017-03-14 2018-09-20 Sunshine Lake Pharma Co., Ltd. Protéines de fusion à double cible comprenant la partie fc d'une immunoglobuline
CN111050786A (zh) 2017-09-08 2020-04-21 百时美施贵宝公司 用于治疗非酒精性脂肪性肝炎(nash)的方法的修饰的成纤维细胞生长因子21(fgf-21)
WO2019123427A1 (fr) 2017-12-22 2019-06-27 Novartis Ag Procédés de traitement de troubles métaboliques avec des variants de fgf21
CN116098989B (zh) 2018-02-08 2026-03-20 广东东阳光药业股份有限公司 Fgf21变体、融合蛋白及其应用
KR20210027426A (ko) * 2018-07-03 2021-03-10 브리스톨-마이어스 스큅 컴퍼니 Fgf21 제제
CN109836486B (zh) * 2019-01-30 2020-09-08 北京双因生物科技有限公司 成纤维生长因子21变体、其融合蛋白及其用途
AU2020230668B2 (en) * 2019-03-05 2025-05-29 Sunshine Lake Pharma Co., Ltd. A polypeptide molecule and application thereof
CN114853908B (zh) 2019-05-16 2024-06-07 浙江道尔生物科技有限公司 一种治疗代谢疾病的融合蛋白
US20220016211A1 (en) 2020-01-08 2022-01-20 Bristol-Myers Squibb Company Fgf-21 conjugate formulations
CN113728013B (zh) 2020-01-11 2022-06-14 北京质肽生物医药科技有限公司 Glp-1和fgf21的融合蛋白的缀合物
WO2022032187A1 (fr) 2020-08-07 2022-02-10 Bristol-Myers Squibb Company Fgf21 combiné à des antagonistes de ccr2/5 pour le traitement de la fibrose
KR102495299B1 (ko) * 2020-11-03 2023-02-06 토드제약 주식회사 Fgf21의 열탄력성을 이용한 fgf21 생산 방법
WO2022115597A1 (fr) 2020-11-25 2022-06-02 Bristol-Myers Squibb Company Méthodes de traitement de maladies du foie
WO2023284822A1 (fr) 2021-07-14 2023-01-19 Beijing Ql Biopharmaceutical Co., Ltd. Polypeptides de fusion pour troubles métaboliques

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
WO2003011213A2 (fr) 2001-07-30 2003-02-13 Eli Lilly And Company Methode de traitement du diabete et de l'obesite
EP2270163A1 (fr) * 2003-12-10 2011-01-05 Eli Lilly and Company Mutéines du facteur de croissance des fibroblastes
EP1789443A1 (fr) 2004-09-02 2007-05-30 Eli Lilly And Company Muteines du facteur de croissance 21 du fibroblaste
BRPI0514790A (pt) * 2004-09-02 2008-06-24 Lilly Co Eli muteìna de fgf-21 de humano, ou um seu peptìdeo biologicamente ativo, método para produzir a muteìna, composição farmacêutica, e, uso da muteìna de fgf-21 de humano
CA2682147C (fr) 2007-03-30 2017-08-08 Ambrx, Inc. Polypeptides fgf-21 modifies, et leurs utilisations
SG193860A1 (en) * 2008-06-04 2013-10-30 Amgen Inc Fgf21 mutants and uses thereof
WO2010065439A1 (fr) * 2008-12-05 2010-06-10 Eli Lilly And Company Variants de facteurde croissance 21 du fibroblaste
AU2010246038A1 (en) 2009-05-05 2011-12-01 Amgen Inc. FGF21 mutants and uses thereof
BRPI1011404B1 (pt) 2009-05-05 2022-05-03 Amgen Inc Polipeptídeos mutantes fgf21, polipeptídeo de fusão, multímero, composição farmacêutica, ácido nucleico isolado, vetor e célula hospedeira

Also Published As

Publication number Publication date
CA2843520A1 (fr) 2013-04-11
CN103906530B (zh) 2016-01-20
BR112014007532A2 (pt) 2017-04-04
JP6060167B2 (ja) 2017-01-11
TN2014000096A1 (en) 2015-07-01
CR20140142A (es) 2014-05-02
IN2014CN00782A (fr) 2015-04-03
EA201490521A1 (ru) 2014-07-30
ZA201400882B (en) 2016-02-24
ECSP14013285A (es) 2014-05-31
US8883726B2 (en) 2014-11-11
AP2014007532A0 (en) 2014-03-31
EP2763689A1 (fr) 2014-08-13
AU2012318956A1 (en) 2014-02-06
PH12014500740A1 (en) 2020-10-19
SG11201401792UA (en) 2014-08-28
EP2763689B1 (fr) 2015-08-12
DOP2014000050A (es) 2014-04-15
TWI461435B (zh) 2014-11-21
IL230754A0 (en) 2014-03-31
CL2014000801A1 (es) 2014-09-12
US20130085098A1 (en) 2013-04-04
KR20140059271A (ko) 2014-05-15
CO6910165A2 (es) 2014-03-31
US8541369B2 (en) 2013-09-24
MX2014004159A (es) 2015-02-12
TW201326198A (zh) 2013-07-01
WO2013052311A1 (fr) 2013-04-11
US20130324460A1 (en) 2013-12-05
PE20142044A1 (es) 2014-12-06
CN103906530A (zh) 2014-07-02
ES2548214T3 (es) 2015-10-14
JP2014530220A (ja) 2014-11-17
AR087973A1 (es) 2014-04-30

Similar Documents

Publication Publication Date Title
EA201490521A1 (ru) Варианты фактора роста фибробластов 21
EA201492053A1 (ru) Белки фактора роста фибробластов 21
EA201492064A1 (ru) Варианты фактора роста фибробластов 21
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
CY1119596T1 (el) Σταθερη φαρμακευτικη συνθεση και μεθοδοι χρησης αυτης
EA201390060A1 (ru) Аннелированные пиримидины и триазины и их применение для лечения и/или профилактики сердечно-сосудистых заболеваний
EA201100138A1 (ru) 4-феноксиметилпиперидины в качестве модуляторов активности gpr119
EA201290209A1 (ru) Новые модуляторы бензопиран киназы
EA201101190A1 (ru) Фармацевтическая композиция, включающая линаглиптин и необязательно ингибитор sglt2, и ее применение
EA201001639A1 (ru) Композиции и способы их получения и применения
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
EA201291336A1 (ru) Замещенные 5-фтор-1н-пиразолопиридины и их применение
UA104626C2 (ru) Анти-vegf антитело и его применение
EA201270480A1 (ru) Новые соединения
CR20130264A (es) Compuestos pirimidinona para uso en el tratamiento de enfermedades o condiciones mediadas por lp-pla2
EA201100691A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты
EA201200551A1 (ru) Фармацевтическая композиция, фармацевтическая дозированная форма, способы их получения и применения для лечения
AR080685A1 (es) Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
EA201200570A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA201300471A1 (ru) Замещенные 6-аминоникотинамиды в качестве модуляторов kcnq2/3
EA201290808A1 (ru) Замещенные конденсированные производные имидазола, фармацевтические композиции и способы их применения
EA201400623A1 (ru) Новые 2h-индазолы в качестве антагонистов рецептора ep
CY1116234T1 (el) Υποκατεστημενα 2-οξυ-κινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3